These findings suggest that the COVID-19 infection affected Iba-1 labeled immune cells in the gray matter in both the AD and the DS cases, with the greatest loss in the DS COVID + cases, which displayed an approximately fourfold lower percentage of staining compared to the control COVID- group. The gene discussed is AIF1; the disease is Alzheimer disease.